What is the recommended management for gonococcal urethritis, including antibiotic regimen, partner treatment, testing, and alternatives for cephalosporin allergy?

Gonococcal Urethritis Management

First-Line Treatment Regimen

The CDC recommends ceftriaxone 500 mg intramuscularly as a single dose PLUS azithromycin 1 g orally as a single dose for uncomplicated gonococcal urethritis. 1, 2, 3

This dual-therapy approach achieves a 99.1% cure rate for urogenital gonorrhea while simultaneously treating chlamydial co-infection, which occurs in 20–50% of gonorrhea cases. 1, 2 The increased ceftriaxone dose from the historical 250 mg to 500 mg preserves a therapeutic reserve against emerging resistance. 1, 3

Rationale for Dual Therapy

• Chlamydial co-infection is present in 20–50% of gonorrhea cases, making presumptive treatment essential even when chlamydia testing is negative. 1, 2
• Dual therapy delays cephalosporin resistance emergence by using two antimicrobials with different mechanisms of action. 1, 2
• Single-dose regimens maximize compliance through directly observed therapy. 4

Alternative Regimens

When Ceftriaxone Is Unavailable

Cefixime 400 mg orally PLUS azithromycin 1 g orally as single doses, with mandatory test-of-cure at 1 week. 1, 5

• Cefixime achieves only 97.4% cure for urogenital infections (versus 99.1% for ceftriaxone) and just 78.9% for pharyngeal infections. 1, 2
• The lower and less sustained bactericidal levels necessitate follow-up testing. 1

For Severe Cephalosporin Allergy

Azithromycin 2 g orally as a single dose, with mandatory test-of-cure at 1 week. 1, 5

• This regimen has only 93% efficacy and causes significant gastrointestinal side effects. 1, 5
• Spectinomycin 2 g intramuscularly is an alternative with 96.7% cure for urogenital infections but only 52% for pharyngeal gonorrhea and has limited availability. 1, 5, 6

Medications That Are Absolutely Contraindicated

Never use fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) due to widespread resistance, despite historical cure rates exceeding 99%. 1, 5, 3

Never use azithromycin 1 g alone for gonorrhea—it achieves only 93% efficacy and promotes rapid resistance development. 1, 2, 5

Partner Management

All sexual partners from the preceding 60 days must be evaluated and treated immediately with the same dual-therapy regimen, regardless of symptoms or test results. 1, 5

Timing-Based Treatment Criteria

• Symptomatic index patient: Treat every partner whose last contact occurred ≤30 days before symptom onset. 1
• Asymptomatic index patient: Treat every partner whose last contact occurred ≤60 days before diagnosis. 1
• Contacts outside these windows: Treat the most recent partner regardless of timing. 1

Expedited Partner Therapy

• Consider providing cefixime 400 mg plus azithromycin 1 g orally when partners cannot access timely evaluation. 1
• Do not use expedited partner therapy for men who have sex with men (MSM) due to high risk of undiagnosed co-existing STDs or HIV. 1

Sexual Activity Restrictions

Patients must abstain from sexual intercourse until therapy is completed for both the patient and all partners AND all individuals are asymptomatic. 1, 5 This prevents ongoing transmission and reinfection, which is the primary cause of apparent treatment failure. 1, 5

Testing and Follow-Up

Initial Testing

• Test for both gonorrhea and chlamydia using nucleic acid amplification tests (NAATs) from all potentially exposed sites. 4
• Screen for syphilis by serology and HIV at the time of gonorrhea diagnosis, as gonorrhea facilitates HIV transmission. 1, 5

Test-of-Cure Requirements

Routine test-of-cure is NOT required after the recommended ceftriaxone-based regimen unless symptoms persist. 1, 2

Mandatory test-of-cure at 1 week is required for:

• Patients receiving cefixime-based regimens 1, 5
• Patients receiving azithromycin 2 g monotherapy 1, 5
• Patients with persistent symptoms after any treatment 1

Reinfection Screening

Retest all patients at 3 months due to high reinfection rates (20–30%), as most post-treatment positive tests represent reinfection rather than treatment failure. 1, 2

Special Populations

Pregnancy

Use ceftriaxone 500 mg intramuscularly PLUS azithromycin 1 g orally as a single dose. 1, 2

Never use quinolones, tetracyclines, or doxycycline in pregnancy due to fetal safety concerns. 1, 5

If severe cephalosporin allergy is documented, use spectinomycin 2 g intramuscularly plus azithromycin 1 g orally. 1

Men Who Have Sex With Men (MSM)

Ceftriaxone is the only recommended treatment due to higher prevalence of resistant strains in this population. 1, 2

Never use quinolones for MSM. 1

HIV-Infected Patients

Use the same treatment regimen as HIV-negative patients. 5 Treatment is particularly vital to prevent increased HIV shedding and transmission risk. 5

Site-Specific Considerations

Pharyngeal Gonorrhea

Ceftriaxone 500 mg intramuscularly is the only reliably effective treatment for pharyngeal infections. 1, 2

• Oral cephalosporins achieve only 78.9% cure for pharyngeal sites. 1, 2
• Spectinomycin has only 52% efficacy for pharyngeal infections and should be avoided. 1, 5
• Pharyngeal gonorrhea is significantly more difficult to eradicate than urogenital or anorectal infections. 1

Gonococcal Conjunctivitis

Ceftriaxone 1 g intramuscularly as a single dose PLUS a single saline eye lavage. 1

Disseminated Gonococcal Infection (DGI)

• Hospitalize for initial therapy. 1
• Ceftriaxone 1 g intramuscularly or intravenously every 24 hours for 24–48 hours until clinical improvement. 1
• Switch to oral cefixime 400 mg twice daily to complete 1 week total therapy. 1
• Assess for endocarditis and meningitis. 1

Treatment Failure Management

If symptoms persist after treatment:

1. Obtain specimens for culture with antimicrobial susceptibility testing immediately from all potentially infected sites. 1, 5
2. Report the case to local public health officials within 24 hours. 1
3. Consult an infectious disease specialist. 1

Salvage Regimens for Suspected Ceftriaxone Failure

• Gentamicin 240 mg intramuscularly PLUS azithromycin 2 g orally (single dose) 1
• Ertapenem 1 g intramuscularly for 3 days 1
• Spectinomycin 2 g intramuscularly PLUS azithromycin 2 g orally 1

Critical Pitfalls to Avoid

• Never skip partner treatment—this is the primary cause of apparent treatment failure. 5
• Never use oral cephalosporins for pharyngeal infections—they have markedly inferior efficacy. 1, 2
• Never assume symptom resolution equals cure when suboptimal regimens were used—test-of-cure is mandatory. 1
• Never use fluoroquinolones regardless of susceptibility testing due to widespread resistance. 1, 5, 3